Vimta Labs Ltd (VIMTALABS) — shareholding pattern, promoter holding, financials and share price
About Vimta Labs Ltd (VIMTALABS)
Vimta Labs Ltd operates in the Healthcare Research, Analytics & Technology industry, within the Healthcare sector. It trades on the NSE as VIMTALABS and on the BSE under scrip code 524394. Its ISIN is INE579C01029.
Incorporated in 1990, Vimta Labs Ltd is a contract research and testing services provider [1]
Vimta Labs Limited is a comprehensive contract research and testing organization serving industries like pharmaceuticals, food, electronics, and environment testing. With expertise in drug discovery and development, it offers pivotal support for numerous sectors.
The company has experienced a commendable 10.2% year-on-year revenue growth as of Q3 FY26, showcasing resilience and effective market penetration. The diverse testing services offered have significantly contributed to these earnings.
Listed peers in Healthcare Research, Analytics & Technology: Take Solutions Ltd, Bilcare Ltd, Jeevan Scientific Technology Ltd, Globalspace Technologies Ltd, Novelix Pharmaceuticals Ltd, Adeshwar Meditex Ltd.
Valuation & Returns
10 Jul 2026At ₹563.7 a share on 10 Jul 2026, Vimta Labs Ltd (VIMTALABS) was valued at a price-to-earnings ratio of 41.41x against an industry P/E of 61.73x and a price-to-book of 7.88x on a book value of ₹71.57 per share as of Mar 2024. Solomo computes return on equity of 19.02% and return on capital employed of 24.27% from filed results. Earnings ratios use consolidated results for the twelve months Mar 2024 to Dec 2024.
- P/E
- 41.41x
- Industry P/E
- 61.73x
- P/B
- 7.88x
- EPS (TTM)
- ₹13.61
- Book value / share
- ₹71.57
- ROE
- 19.02%
- ROCE
- 24.27%
- ROA
- 15.2%
- Debt / equity
- 0.06x
- Dividend yield
- 0.35%
- EBITDA margin
- 35.54%
- 52-week range
- ₹377.3 – ₹902.85
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2024In the year ended Mar 2024, Vimta Labs Ltd (VIMTALABS) reported revenue of ₹318 crore, net profit of ₹41 crore and earnings per share of ₹9.26. That compares with revenue of ₹318 crore and net profit of ₹48 crore in Mar 2023. Figures are consolidated, as filed with the exchanges.
In the quarter ended Dec 2024, revenue was ₹90 crore and net profit ₹22 crore (consolidated).
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 181 | 211 | 278 | 318 | 318 |
| Net profit (₹ cr) | 7 | 21 | 41 | 48 | 41 |
| EPS (₹) | 1.55 | 4.84 | 9.35 | 10.87 | 9.26 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 11.42% | 14.27% | 8.93% | 0.02% |
| Profit growth | 24.75% | 29.53% | 17.90% | -14.86% |
| Stock price CAGR | 28% | 30% | 35% | 19% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 35.67% of Vimta Labs Ltd (VIMTALABS) (down 0.18 pp QoQ), foreign institutional investors (FII) hold 4.42% and domestic institutional investors (DII) hold 0.37%. Market capitalisation was ₹2,518 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: EUROFINS ANALYTICAL SERVICES INDIA PVT LTD 19.72%, LCGC CHROMATOGRAPHY SOLUTIONS PRIVATE LIMITED 9.33%, BARCA GLOBAL MASTER FUND LP 2.27%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 35.67% | - | 4.42% | 0.37% | 64.33% |
| Mar 2026 | 35.85% | - | 4.89% | 0.14% | 64.15% |
| Dec 2025 | 35.9% | - | 4.59% | 0.11% | 64.1% |
| Sep 2025 | 35.99% | - | 4.33% | 0.87% | 64.01% |
| Jun 2025 | 36.67% | - | 3.49% | 1.42% | 63.33% |
| Mar 2025 | 36.7% | - | 3.66% | 1.43% | 63.3% |
| Dec 2024 | 36.76% | - | 3.81% | 1.16% | 63.24% |
| Sep 2024 | 36.89% | - | 3.31% | 0% | 63.11% |